Sugammadex: Nursing Drug Guide, Post-Reversal Monitoring & NCLEX Review

Bridion is the primary brand name for sugammadex in the United States and European Union. The generic name sugammadex should appear on the MAR, infusion record, and allergy list. Verify the neuromuscular blocker being reversed (rocuronium or vecuronium) on the anesthesia record before accepting a reversal order—sugammadex will not reverse other agents.

Sugammadex is indicated for reversal of neuromuscular blockade induced by rocuronium or vecuronium in adult and pediatric patients undergoing surgery. PACU and perioperative nurses most often encounter it after laparotomy, orthopedic, or other procedures where rapid, reliable reversal is needed instead of waiting for spontaneous recovery or using anticholinesterase reversal.

↔On a small screen, swipe or scroll sideways to see the full table.

Sugammadex is a modified gamma-cyclodextrin that selectively encapsulates rocuronium and vecuronium in plasma, forming an inactive complex that cannot bind acetylcholine receptors at the neuromuscular junction. Free neuromuscular blocker concentration falls, allowing neuromuscular transmission to resume. Because binding is selective, sugammadex does not reverse depolarizing block from succinylcholine or non-aminosteroid NMBAs. Recurrence of block can occur if encapsulated drug redistributes or if inadequate dosing was given for the depth of block—nurses must not equate drug administration with completed recovery.

All doses are based on actual body weight and given as a single IV bolus over approximately 10 seconds. Dose selection depends on depth of block assessed by TOF or PTC at the time of administration.

Missed dose: Not applicable for single-bolus reversal. If inadequate reversal occurs, anesthesia determines whether additional dosing is appropriate—nurses monitor and escalate rather than repeat independently.

↔On a small screen, swipe or scroll sideways to see the full table.

Pretreatment checks

• Confirm the neuromuscular blocker was rocuronium or vecuronium—not succinylcholine or another agent
• Verify actual body weight, ordered mg/kg dose, and depth of block (TOF/PTC) supporting the dose tier
• Review renal function, hormonal contraceptive use, and history of sugammadex or cyclodextrin hypersensitivity
• Ensure ventilatory support, suction, reversal medications (e.g., atropine), and anesthesia contact are available

Contraindications

• Hypersensitivity to sugammadex or any formulation component

Important warnings and interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Intravenous bolus only—administer over approximately 10 seconds per BRIDION labeling. Given by or under anesthesia supervision in most settings; PACU nurses administer when ordered and monitor response.

• Calculate dose from actual body weight (kg) × mg/kg; independent double-check high-risk weight-based bolus
• Use dedicated syringe/line when possible; do not co-infuse with verapamil, ondansetron, or ranitidine
• Maintain ventilatory support during and after bolus until spontaneous respiration and patent airway confirmed
• Document time, dose, TOF/PTC before dose, and initial recovery assessment after administration

• TOF count rises toward 4/4 with sustained tetanic fade improvement
• Spontaneous respiratory effort with adequate tidal volume and oxygenation
• Ability to follow commands, sustain head lift for 5 seconds, or meet institutional extubation criteria
• Stable heart rate and blood pressure without new bradycardia or hypotension

Initial improvement can occur within minutes, but labeling explicitly warns that recurrence of neuromuscular blockade may follow—response must be sustained, not a single good TOF reading.

Escalate immediately—these findings may indicate recurrent block, anaphylaxis, or hemodynamic collapse despite initial reversal.

• Declining TOF after prior recovery (e.g., 4/4 → 2/4 → 0/4)
• Shortness of breath, shallow respirations, apnea, or falling SpO₂ despite oxygen
• Inability to sustain head lift, grip strength loss, or generalized weakness after apparent recovery
• Marked bradycardia (e.g., HR <50) or hypotension new after sugammadex—administer atropine per protocol and notify anesthesia
• Urticaria, facial swelling, bronchospasm, or cardiovascular collapse suggesting anaphylaxis
• Persistent nausea and vomiting with aspiration risk in a patient with incomplete airway reflexes

↔On a small screen, swipe or scroll sideways to see the full table.

There is no specific antidote for sugammadex overdose. Management is supportive per BRIDION labeling.

Clinical notes

• One reported case of 40 mg/kg (10-fold therapeutic dose) did not cause significant adverse effects
• High-flux hemodialysis may remove approximately 70% of sugammadex in 3–6 hours
• Monitor airway, ventilation, hemodynamics, and neurologic status; involve anesthesia, nephrology, and pharmacy as indicated

• Sugammadex vs neostigmine—both reverse NMBAs but different mechanisms, dosing, and anticholinergic co-therapy; verify which reversal agent is ordered
• Bridion vs other IV anesthetics—store and label syringes clearly in PACU; do not confuse with propofol or opioid syringes
• mg/kg calculation errors—4 mg/kg for a 90 kg patient is 360 mg; double-check weight and math
• Wrong NMBA assumed—sugammadex only reverses rocuronium/vecuronium; succinylcholine block requires time and supportive care
• “Reversed = recovered”—documenting administration without TOF trend is a common monitoring gap

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Respiratory rate, depth, SpO₂, and need for ventilatory support until spontaneous respiration established
• TOF/PTC trends until sustained neuromuscular recovery (typically TOF ratio ≥0.9 per institutional extubation criteria)
• Heart rate and blood pressure—especially bradycardia in first 30 minutes post-bolus
• Level of consciousness, ability to protect airway, and presence of nausea/vomiting

Document

• Dose (mg and mg/kg), actual body weight used, time, and TOF/PTC before administration
• Serial TOF, respiratory assessments, and time spontaneous ventilation confirmed
• Contraceptive counseling if applicable; anesthesia notification for recurrent block or bradycardia

• You received a medicine to help your muscles wake up after anesthesia—you may still feel weak until fully recovered; tell staff if breathing feels hard or muscles feel heavy again
• If you use hormonal birth control (pill, patch, ring), use a backup non-hormonal method for 7 days after this medicine
• Report dizziness, severe nausea, rash, or chest discomfort to your nurse immediately
• Do not drive or make important decisions until anesthesia staff clear you—muscle strength and alertness must return first

Do not give and contact anesthesia/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Practice NCLEX-style clinical judgment practice for sugammadex using a PACU case panel (MAR, labs, vitals, nursing notes), then work through priority action, cue recognition (SATA), trend interpretation, matrix urgency sorting, documentation cloze, and ordered response—recognise cues → analyse → prioritise → act → evaluate outcomes around post-reversal monitoring and recurrent neuromuscular blockade.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.